Expression of vascular endothelial growth factor by photodynamic therapy with mono-l-aspartyl chlorin e6 (NPe6) in oral squamous cell carcinoma

Oral Oncology

Volumn 43, Issue 6, 2007, Pages 544-550

  Nakagawa, Hiroshi ^a   Matsumiya, Tomoh ^a   Sakaki, Hirotaka ^a   Imaizumi, Tadaatsu ^a   Kubota, Kousei ^a   Kusumi, Akinori ^a   Kobayashi, Wataru ^a   Kimura, Hiroto ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

c fos; c jun; Desfferioxamine; HSC 3 cell; Mono l aspartyl chlorin e6; N acetyl l cysteine; Photodynamic therapy; Vascular endothelial growth factor

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCYSTEINE; CYCLOHEXIMIDE; DEFEROXAMINE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHOTOSENSITIZING AGENT; PROTEIN C FOS; PROTEIN C JUN; SCAVENGER; TALAPORFIN; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INCUBATION TIME; MOUTH CARCINOMA; OXIDATIVE STRESS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CYCLOHEXIMIDE; DEFEROXAMINE; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FREE RADICAL SCAVENGERS; GENES, FOS; GENES, JUN; HUMANS; IMIDAZOLES; MOUTH NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROTEIN SYNTHESIS INHIBITORS; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIDEROPHORES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34249797552     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2006.03.020     Document Type: Article

References (39)

1. Pass H.I. Photodynamic therapy in oncology: mechanisms and clinical use. J Natl Cancer Inst 85 (1993) 443-456
2. Hopper C. The role of photodynamic therapy in the management of oral cancer and precancer. Eur J Cancer B 32b (1996) 71-72
3. Ma G., Ikeda H., Inokuchi T., and Sano K. Effect of photodynamic therapy using 5-aminolevulinic acid on 4-nitroquinoline-1-oxide-induced premalignant and malignant lesions of mouse tongue. Oral Oncol 35 (1999) 120-124
4. Chen H.M., Chen C.T., Yang H., Lee M.I., Kuo M.Y., et al. Successful treatment of an extensive verrucous carcinoma with topical 5-aminolevulinic acid-mediated photodynamic therapy. J Oral Pathol Med 34 (2005) 253-256
5. Gluckman J.L., Waner M., Shumrick K., and Peerless S. Photodynamic therapy. A viable alternative to conventional therapy for early lesion of the upper aerodigestive tract?. Arch Otolaryngol Head Neck Surg 112 (1986) 949-952
6. Fan K.F., Hopper C., Speight P.M., Buonaccorsi G., MacRobert A.J., and Bown S.G. Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Cancer 78 (1996) 1374-1383
7. Grant W.E., Speight P.M., Hopper C., and Bown S.G. Photodynamic therapy: an effective, but non-selective treatment for superficial cancers of the oral cavity. Int J Cancer 71 (1997) 937-942
8. Dube A., Sharma S., and Gupta P.K. Evaluation of chlorin p6 for photodynamic treatment of squamous cell carcinoma in the hamster cheek pouch model. Oral Oncol (2005) [Epub ahead of print]
9. Uehara M., and Inokuchi T. Hyperthermic photodynamic therapy combined with topical administration of OK-432 in the mouse carcinoma. Oral Oncol 39 (2003) 184-189
10. Uehara M., Inokuchi T., Sano K., Sekine J., and Ikeda H. Cell kinetics of mouse tumour subjected to photodynamic therapy: evaluation by proliferating cell nuclear antigen immunohistochemistry. Oral Oncol 35 (1999) 93-97
11. Kobayashi W., Liu Q., Nakagawa H., Sakaki H., Teh B., Matsumiya T., et al. Photodynamic therapy with mono-l-aspartyl chlorin e6 can cause necrosis of squamous cell carcinoma of tongue: experimental study on an animal model of nude mouse. Oral Oncol (2005) [Epub ahead of print]
12. Roberts W.G., Shiau F.Y., Nelson J.S., Smith K.M., and Berns M.W. In vitro characterization of monoaspartyl chlorin e6 and diaspartyl chlorin e6 for photodynamic therapy. J Natl Cancer Inst 80 (1988) 330-336
13. Ferrario A., Kessel D., and Gomer C.J. Metabolic properties and photosensititizing responsiveness of mono-l-aspartyl chlorin e6 in a mouse tumor model. Cancer Res 52 (1992) 2890-2893
14. Roberts W.G., Smith K.M., McCullough J.L., and Berns M.W. Skin photosensitivity and photodestruction of several potential photodynamic sensitizers. Photochem photobiol 49 (1989) 431-438
15. Kaneko T., Chiba H., Yasuda T., and Kusama K. Detection of photodynamic therapy-induced early apoptosis in human salivary gland tumor cells in vitro and in a mouse tumor model. Oral Oncol 40 (2004) 787-792
16. Dougherty T.J., Gomer C.J., Henderson B.W., et al. Photodynamic therapy. J Natl Cancer Inst 90 (1998) 889-905
17. Sitnik T.M., Hampton J.A., and Henderson B.W. Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate. Br J Cancer 77 (1998) 1386-1394
18. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989) 1306-1309
19. Claffey K.P., Brown L.F., del Aguila L.F., et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 56 (1996) 172-181
20. Uehara M., Inokuchi T., Sano K., and ZuoLin W. Expression of vascular endothelial growth factor in mouse tumours subjected to photodynamic therapy. Eur J Cancer 37 16 (2001) 2111-2115
21. Ferrario A., von Tiehl K.F., Rucker N., Schwarz M.A., Gill P.S., and Gomer C.J. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 60 (2000) 4066-4069
22. Nose K., Shibanuma M., Kikuchi K., Kageyama H., Sakiyama S., and Kuroi T. Transcriptional activation of early-response genes by hydrogen peroxide in a mouse osteobalastic cell line. Eur J Biochem 201 (1991) 99-106
23. Chiu R., Boyle W.J., Meek J., Smeal T., Hunter T., and Karin M. The c-fos protein interacts with c-jun/AP-1 to stimulate transcriptional of AP-1 responsive genes. Cell 54 (1988) 541-552
24. Yu J., Bian D., Mahanivong C., Cheng R.K., Zhou W., and Huang S. p38 Mitogen-activated protein kinase regulation of endothelial cell migration depends on urokinase plasminogen activator expression. J Biol Chem 279 (2004) 50446-50454
25. Assefa Z., Vantieghem A., Declercq W., et al. The activation of the c-Jun N-terminal kinase and p38 mitogenactivated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin. J Biol Chem 274 (1999) 8788-8796
26. Han J., Lee J.D., Bibbs L., and Ulevitch R.J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265 (1994) 808-811
27. Momose F., Araida T., Negishi A., Ichijo H., Shioda S., et al. Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell carcinomas. J Oral Pathol Med 18 (1989) 391-395
28. An W.G., Kanekal M., Simon M.C., Maltepe E., Blagosklonny M.V., and Neckers L.M. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392 (1998) 405-408
29. Grossweiner L.I., Hill J.H., and Lobraico R.V. Photodynamic therapy of head and neck squamous cell carcinoma: optical dosimetry and clinical trial. Photochem Photobiol 46 (1987) 911-917
30. Kick G., Messer G., Plewig G., Kind P., and Goetz A.E. Strong and prolonged induction of c-jun and c-fos proto-oncogenes by photodynamic therapy. Br J Cancer 74 (1996) 30-36
31. Klotz L.O., Fritsch C., Briviba K., Tsacmacidis N., Schliess F., and Sies H. Activation of JNK and p38 but not ERK MAP kinases in human skin cells by 5-aminolevulinate-photodynamic therapy. Cancer Res 58 (1998) 4297-4300
32. Rousseau S., Houle F., Landry J., and Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 15 (1997) 2169-2177
33. Gubits R.M., and Fairhurst J.L. C-fos mRNA levels are increased by the cellular stressors, heat shock and sodium arsentie. Oncogene 3 (1988) 163-168
34. Buscher M., Rahmsdorf H.J., Liftin M., Karin M., and Herrlich P. Activation of the c-fos gene by UV and phorbol ester: different signal transduction pathways converge to the same enhancer element. Oncogene 3 (1988) 301-311
35. Sherman M.L., Datta R., Hallahan D.E., Weichselbaum R.R., and Kufe D.W. Ionizing radiation regulates expression of the c-jun protooncogene. Proc Natl Acad Sci USA 87 (1990) 5663-5666
36. Im S.A., Gomez-Manzano C., Fueyo J., et al. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 59 (1999) 895-900
37. Goldman C.K., Kendall R.L., Cabrera G., et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 95 (1998) 8795-8800
38. Aruoma O.I., Halliwell B., Hoey B.M., and Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorus acid. Free Radic Biol Med 6 (1989) 593-597
39. 2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J 12 (1993) 2005-2015